Q-omics provides the consensus-scored KRTAP21-2 profile across patient tissues and cancer cell-line models. KRTAP21-2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, KRTAP21-2 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, KRTAP21-2 RNA expression shows 4,357 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CESC, BRCA, and STAD as cancer lineages where KRTAP21-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRTAP21-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRTAP21-2 survival associations across molecular data types. KRTAP21-2 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRTAP21-2 RNA expression–survival associations across cancer types. High KRTAP21-2 expression shows unfavorable associations in COAD, LIHC, MESO and TGCT, but favorable associations in CESC and UCS. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .011). Together, the overview and detailed table identify CESC as the clearest survival context for KRTAP21-2 RNA expression.
This table summarizes KRTAP21-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for KRTAP21-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRTAP21-2 shows higher tumor expression in BRCA, LUSC, KIRP and THCA. The BRCA box plot shows higher KRTAP21-2 RNA expression in tumor versus normal tissue (log2 FC = +0.103, t-test p = .004).
This table shows molecular features associated with KRTAP21-2 in patient tissues and cancer cell lines. In patient samples, KRTAP21-2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, KRTAP21-2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SKIN.
